The significance of cytokines, chemical composition, and murine embryo development in hydrosalpinx fluid for predicting the IVF outcome in women with hydrosalpinx.
BACKGROUND
The aim of this study was to determine whether differences in cytokine concentrations, chemical composition, and murine embryogenesis in hydrosalpinx fluid could be observed between women with hydrosalpinx who achieved and did not achieve pregnancy.


METHODS
Hydrosalpinx fluids were collected from 39 infertile women participating in an IVF-embryo transfer programme at a university teaching hospital. The fluids were analysed for concentrations of cytokine concentration (epidermal growth factor, interferon-gamma, leukaemia inhibitory factor, and tumour necrosis factor-alpha) and chemical composition. Mouse embryos were cultured in medium with various concentrations (0, 10, 50, 100%) of hydrosalpinx fluid.


RESULTS
Logistic regression demonstrated that a murine blastocyst formation rate >or=53.3% in 50% hydrosalpinx fluid (OR = 16.6, 95% CI 2.4-116.1, P = 0.005) and patient age (OR = 0.778, 95% CI 0.61-0.99, P = 0.045) were independent predictors of IVF outcome. The diagnostic accuracy did not significantly improve when age and number of good quality embryos transferred was taken into account. The chemical composition and cytokine concentrations of hydrosalpinx fluid were not predictive of subsequent IVF outcome.


CONCLUSIONS
The mouse embryo assay of hydrosalpinx fluid might potentially serve as a predictor of subsequent IVF outcome in women with hydrosalpinx. This technique may be useful in selecting appropriate treatment options for patients with hydrosalpinx undergoing IVF treatment.
Chen
Chin-Der
CD
Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.
Yang
Jehn-Hsiahn
JH
Lin
Ko-Chen
KC
Chao
Kuang-Han
KH
Ho
Hong-Nerng
HN
Yang
Yu-Shih
YS
D000328:Adult; D000818:Animals; D003470:Culture Media; D046508:Culture Techniques; D016207:Cytokines / Q000032:analysis*; D004624:Embryo Transfer; D005314:Embryonic and Fetal Development; D004815:Epidermal Growth Factor / Q000032:analysis; D005122:Exudates and Transudates / Q000737:chemistry*; D005184:Fallopian Tube Diseases / Q000378:metabolism*; D005260:Female; D005307:Fertilization in Vitro; D006131:Growth Inhibitors / Q000032:analysis; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D016015:Logistic Models; D008222:Lymphokines / Q000032:analysis; D051379:Mice; D008813:Mice, Inbred ICR; D011247:Pregnancy; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D003470:Culture Media; D016207:Cytokines; D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; C507838:Lif protein, mouse; D008222:Lymphokines; D014409:Tumor Necrosis Factor-alpha; D004815:Epidermal Growth Factor; D007371:Interferon-gamma